NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novo Nordisk A/S (CO: NOVO-B)

 
NOVO-B Technical Analysis
5
As on 11th Jul 2023 NOVO-B STOCK Price closed @ 1034.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 778.31 & Strong Buy for SHORT-TERM with Stoploss of 694.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVO-BSTOCK Price

Open 1060.80 Change Price %
High 1068.60 1 Day -27.20 -2.56
Low 1026.20 1 Week -64.80 -5.89
Close 1034.60 1 Month -103.00 -9.05
Volume 1347224 1 Year 425.70 69.91
52 Week High 1179.80 | 52 Week Low 608.90
 
CO Denmark Most Active Stocks
SAS-DKK 0.23 0.00%
SAS 0.23 0.00%
TRYG 134.80 -6.62%
AMBU-B 103.75 -4.38%
VWS 179.82 2.07%
NOVO-B 1034.60 -2.56%
ALMB 11.09 -0.54%
GREENH 10.50 1.94%
DANSKE 166.10 1.10%
BLVIS-A 0.40 -18.37%
 
CO Denmark Top Gainers Stocks
NORD 2.10 19.32%
NORD 2.10 19.32%
DKIEEU 249.00 15.81%
HYDRCT 1.69 10.46%
TGAMES 4.37 9.25%
ENALYZ 2.50 8.70%
ODICO 1.53 6.25%
CEMAT 0.71 5.97%
VIRO 22.10 5.24%
VALUER 0.21 5.00%
 
CO Denmark Top Losers Stocks
ASTRLS 1.07 -38.15%
ORPHA 1.21 -21.94%
BLVIS-A 0.40 -18.37%
LEDIBOND 0.40 -11.11%
ERRIA 4.15 -8.39%
HYPE 3.06 -8.38%
TRYG 134.80 -6.62%
NTR-B 6.40 -6.43%
HAPPY 0.18 -5.26%
STENO 3.87 -4.68%
 
 
NOVO-B
Daily Charts
NOVO-B
Intraday Charts
Whats New @
Bazaartrend
NOVO-B
Free Analysis
 
NOVO-B Important Levels Intraday
RESISTANCE1116.30
RESISTANCE1090.10
RESISTANCE1073.90
RESISTANCE1057.71
SUPPORT1011.49
SUPPORT995.30
SUPPORT979.10
SUPPORT952.90
 
NOVO-B Forecast April 2024
4th UP Forecast1285.69
3rd UP Forecast1205.16
2nd UP Forecast1155.39
1st UP Forecast1105.61
1st DOWN Forecast963.59
2nd DOWN Forecast913.81
3rd DOWN Forecast864.04
4th DOWN Forecast783.51
 
NOVO-B Weekly Forecast
4th UP Forecast1228.07
3rd UP Forecast1166.02
2nd UP Forecast1127.67
1st UP Forecast1089.32
1st DOWN Forecast979.88
2nd DOWN Forecast941.53
3rd DOWN Forecast903.18
4th DOWN Forecast841.13
 
NOVO-B Forecast2024
4th UP Forecast2148.41
3rd UP Forecast1791.2
2nd UP Forecast1570.41
1st UP Forecast1349.61
1st DOWN Forecast719.59
2nd DOWN Forecast498.79
3rd DOWN Forecast278
4th DOWN Forecast-79.21
 
 
NOVO-B Other Details
Segment EQ
Market Capital 1565371138048.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
NOVO-B Address
NOVO-B
 
NOVO-B Latest News
 
Your Comments and Response on Novo Nordisk A/S
 
NOVO-B Business Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Allé 1, Bagsvaerd, Denmark, 2880
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service